279 related articles for article (PubMed ID: 33547198)
1. Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas.
Mudianto T; Campbell KM; Webb J; Zolkind P; Skidmore ZL; Riley R; Barnell EK; Ozgenc I; Giri T; Dunn GP; Adkins DR; Griffith M; Egloff AM; Griffith OL; Uppaluri R
Clin Cancer Res; 2021 Apr; 27(8):2326-2339. PubMed ID: 33547198
[TBL] [Abstract][Full Text] [Related]
2. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.
Coggins GE; Farrel A; Rathi KS; Hayes CM; Scolaro L; Rokita JL; Maris JM
Cancer Res; 2019 Dec; 79(24):6204-6214. PubMed ID: 31672841
[TBL] [Abstract][Full Text] [Related]
3. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
4. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
[TBL] [Abstract][Full Text] [Related]
5. Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib.
Vigoda M; Mathieson C; Evans N; Hale C; Jennings J; Lucero O; Jeng S; Bottomly D; Clayburgh D; Andersen P; Li R; Petrisor D; Tyner JW; McWeeney S; Kulesz-Martin M
Cancer Biol Ther; 2022 Dec; 23(1):310-318. PubMed ID: 35343367
[TBL] [Abstract][Full Text] [Related]
6. Combined BET and MEK Inhibition synergistically suppresses melanoma by targeting YAP1.
Hu R; Hou H; Li Y; Zhang M; Li X; Chen Y; Guo Y; Sun H; Zhao S; Liao M; Cao D; Yan Q; Chen X; Yin M
Theranostics; 2024; 14(2):593-607. PubMed ID: 38169595
[No Abstract] [Full Text] [Related]
7. The synergistic antitumor effect of combination therapy with a MEK inhibitor and YAP inhibitor on pERK-positive neuroblastoma.
Takemoto M; Tanaka T; Tsuji R; Togashi Y; Higashi M; Fumino S; Tajiri T
Biochem Biophys Res Commun; 2021 Sep; 570():41-46. PubMed ID: 34271435
[TBL] [Abstract][Full Text] [Related]
8. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
[TBL] [Abstract][Full Text] [Related]
9. A Novel Neoplastic Fusion Transcript,
Liu CC; Veeraraghavan J; Tan Y; Kim JA; Wang X; Loo SK; Lee S; Hu Y; Wang XS
Clin Cancer Res; 2021 Feb; 27(3):785-798. PubMed ID: 33172895
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.
Day TA; Shirai K; O'Brien PE; Matheus MG; Godwin K; Sood AJ; Kompelli A; Vick JA; Martin D; Vitale-Cross L; Callejas-Varela JL; Wang Z; Wu X; Harismendy O; Molinolo AA; Lippman SM; Van Waes C; Szabo E; Gutkind JS
Clin Cancer Res; 2019 Feb; 25(4):1156-1164. PubMed ID: 30420444
[TBL] [Abstract][Full Text] [Related]
11. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
[No Abstract] [Full Text] [Related]
12. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
[TBL] [Abstract][Full Text] [Related]
13. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Coan JP; Pearson HE; Bahrar H; Fowler TL; Bednarz BP; Saha S; Yang D; Gill PS; Lingen MW; Saloura V; Villaflor VM; Salgia R; Kimple RJ; Wheeler DL
Clin Cancer Res; 2015 Jun; 21(11):2601-12. PubMed ID: 25767293
[TBL] [Abstract][Full Text] [Related]
14. Mitogen-activated protein kinase inhibition-induced modulation of epidermal growth factor receptor signaling in human head and neck squamous cell carcinoma.
Xie G; Zhu A; Gu X
Head Neck; 2021 Jun; 43(6):1721-1729. PubMed ID: 33533173
[TBL] [Abstract][Full Text] [Related]
15. YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4.
Chen N; Golczer G; Ghose S; Lin B; Langenbucher A; Webb J; Bhanot H; Abt NB; Lin D; Varvares M; Sattler M; Egloff AM; Joh R; Uppaluri R; Emerick KS; Lawrence MS; Saladi SV
Cell Rep; 2022 Jun; 39(11):110970. PubMed ID: 35705032
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.
Osman AA; Arslan E; Bartels M; Michikawa C; Lindemann A; Tomczak K; Yu W; Sandulache V; Ma W; Shen L; Wang J; Singh AK; Frederick MJ; Spencer ND; Kovacs J; Heffernan T; Symmans WF; Rai K; Myers JN
Clin Cancer Res; 2023 Apr; 29(7):1344-1359. PubMed ID: 36689560
[TBL] [Abstract][Full Text] [Related]
17. Loss of TP63 Promotes the Metastasis of Head and Neck Squamous Cell Carcinoma by Activating MAPK and STAT3 Signaling.
Lakshmanachetty S; Balaiya V; High WA; Koster MI
Mol Cancer Res; 2019 Jun; 17(6):1279-1293. PubMed ID: 30910837
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
[TBL] [Abstract][Full Text] [Related]
19. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
20. AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
McDaniel NK; Iida M; Nickel KP; Longhurst CA; Fischbach SR; Rodems TS; Kranjac CA; Bo AY; Luo Q; Gallagher MM; Welke NB; Mitchell KR; Schulz AE; Eckers JC; Hu R; Salgia R; Hong S; Bruce JY; Kimple RJ; Wheeler DL
Clin Cancer Res; 2020 Aug; 26(16):4349-4359. PubMed ID: 32439698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
